Fortis may be out of F&O if results delayed

The National Stock Exchange of India on Thursday said it will exclude Fortis Healthcare from the derivatives segment if the company fails to submit its financial results for the September and December quarter by March 1, reports Our Bureau.

So far, Fortis Healthcare has failed to submit its quarterly financial results for the September and December quarter, said NSE. Fortis has intimated to exchanges that its board will consider results for the two quarters in meeting on February 28.

  • Related Posts

    Lilly launches Mounjaro KwikPen in India

    Mumbai, August 14, 2025 — Eli Lilly and Company (India) has rolled out the Mounjaro (tirzepatide) KwikPen across the country, expanding treatment choices for people with type-2 diabetes and those…

    Fortis Q1 Profit Jumps 57%; Expansion Drives Growth

      Gurugram, August 7 – http://Fortis HealthcareFortis Healthcare has reported a 57% year-on-year increase in its net profit for the first quarter of FY2025. The hospital chain posted ₹260 crore…

    Leave a Reply

    Your email address will not be published. Required fields are marked *

    You Missed

    4yo snakebite victim given anti-rabies shot at Sambhal hosp; pharmacist removed from duty

    4yo snakebite victim given anti-rabies shot at Sambhal hosp; pharmacist removed from duty

    Delhi High Court sets aside FSSAI order asking Red Bull India to drop ‘energy’ from its drinks

    Delhi High Court sets aside FSSAI order asking Red Bull India to drop ‘energy’ from its drinks

    Haryana to use Ayushman, Chirayu claim money for hospital staff incentives and upgrades: CM

    Haryana to use Ayushman, Chirayu claim money for hospital staff incentives and upgrades: CM

    Indian speciality drugs get zero duty as US widens 100% tariff on patented medicines

    Indian speciality drugs get zero duty as US widens 100% tariff on patented medicines

    Low-dose CT screening lowers lung cancer deaths by 16% in high-risk people: IARC

    Low-dose CT screening lowers lung cancer deaths by 16% in high-risk people: IARC

    Krsnaa Diagnostics board clears sale of diagnostic equipment worth up to Rs 120 crore

    Krsnaa Diagnostics board clears sale of diagnostic equipment worth up to Rs 120 crore